Natera partnered with Kupando Therapeutics to use Natera’s Latitude circulating tumor DNA (ctDNA) molecular residual disease assay in a Phase I skin cancer trial in Germany. The study will track serial ctDNA dynamics in patients treated with Kupando’s immunotherapy candidate KUP-101, with MRD testing performed at multiple time points.